A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Multiple Myeloma Clinical Trial

Official title:

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01829971
• Other study ID #: MRX34-101
• Status: Terminated
• Phase: Phase 1
• First received: April 8, 2013
• Last updated: September 26, 2016
• Start date: April 2013
• Est. completion date: May 2017

Study information

• Verified date: September 2016
• Source: Mirna Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationKorea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.

Description:

This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety, Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in patients with unresectable primary liver cancer or advanced or metastatic cancer with or without liver involvement or hematologic malignancies. MRX34 will be administered daily x 5 with 2 weeks off (total of 21 days) for 3 cycles followed by a no-treatment observation period.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 155
• Est. completion date: May 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged = 18 years

2. Patients with histologically confirmed viral related hepatocellular, SCLC, non-cutaneous/ non-uveal melanoma, ovarian, TNBC, Sarcoma, Bladder and RCC.

3. Eastern Cooperative Oncology Group (ECOG) performance status = 1

4. Acceptable liver function:

• Total bilirubin = 1.5 times the upper limit of normal (ULN); for patients with hepatocellular carcinoma only, total bilirubin = 3 mg/dL (i.e. Child-Pugh Score for bilirubin is no greater than 2).

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) = 5 x ULN.

5. Acceptable renal function:

• Serum creatinine = 1.5 times the ULN, or calculated creatinine clearance = 60 mL/min/1.73 m2 for patients with creatinine levels above 1.5 times the institutional normal

6. Acceptable hematological status:

• Absolute Neutrophil Count (ANC) = 1500 cells/mm3

• Platelet count = 100,000 plts/mm3 (without transfusion); = 75,000 plts/mm3 for patients with hepatocellular carcinoma only. For hematologic malignancy patients blood counts cited above do not apply

• Hemoglobin = 9 g/dL

• For the hematologic malignancy patients, blood count values cited above do not apply.

7. Prothrombin time (PT) or International Normalized Ratio (INR) = 1.25 x ULN; for patients with hepatocellular carcinoma only, INR <1.7 or prothrombin time (PT) or < 4 seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation parameter); for patients with hepatocellular carcinoma only, serum albumin > 2.8 g/dL (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic malignancy patients, the coagulation and albumin status cited above do not apply

8. For patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6) disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no greater than 2 and clinically irrelevant; for the determination of the Child-Pugh Class.

Exclusion Criteria:

1. Myocardial infarction within the past 6 months, unstable and/or symptomatic arrhythmia, or evidence of ischemia on ECG.

2. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.

3. Pregnant or nursing women.

4. Known infection with human immunodeficiency virus (HIV).

5. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, heart failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.

6. Patients with recent history of hemorrhage and patients predisposed to hemorrhage due to coagulopathies or structural anomalies.

7. Patients who require treatment with therapeutic doses of coumadin-type anticoagulants (maximum daily dose of 1mg allowed for port line patency permitted).

8. Patients with cirrhosis classed as Child-Pugh B or C.

9. Patients with central nervous system (CNS) metastasis. Intrathecal chemotherapy is allowed for patients who require CNS prophylaxis or therapy.

10. Patients for whom dexamethasone is contraindicated.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Liver Neoplasms
• Lymphoma
• Melanoma
• Multiple Myeloma
• NSCLC
• Primary Liver Cancer
• Renal Cell Carcinoma
• SCLC

Intervention

Drug:
• MRX34
micro RNA therapy

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital, Yonsie University Health System	Seoul	Seodaemun-Gu
United States	Texas Oncology Dallas	Dallas	Texas
United States	UT Southwestern Medical Center	Dallas	Texas
United States	MD Anderson Cancer Center	Houston	Texas
United States	Uthscsa/Ctrc	San Antonio	Texas
United States	Mayo Clinic Arizona	Scottsdale	Arizona
United States	Virginia G. Piper Cancer Center	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Mirna Therapeutics, Inc.	Cancer Prevention Research Institute of Texas

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)	Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle	18 months	Yes
Secondary	Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing		18 months	No
Secondary	Number of patients with evidence of clinical activity of MRX34		18 months	No